LEGN241115P47500
- 3.70
- 0.000.00%
Legend Biotech Newsroom
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $82
Morgan Stanley Remains a Buy on Legend Biotech (LEGN)
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
China Data Point to Gradual Improvement, but Tariff Risk Looms
Hillhouse HHLR Q3 hold positions: Chinese concept stocks hold an absolute dominant position, and the total market value of hold positions grew by more than 10%!
①HHLR Advisors, a subsidiary of Hillhouse Capital, saw its total market cap of US stocks holding positions grow by over 10% in the third quarter, with 9 of the top ten heavy positions being Chinese concept stocks; ②HHLR Advisors continued to hold heavy positions in Chinese concept stocks in the third quarter, with the market cap of Chinese concept stocks increasing from 85% in the second quarter to 93% in the third quarter.
Legend Biotech Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Legend Biotech (LEGN) Gets a Buy From Truist Financial
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $83
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
Express News | HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Legend Biotech Analyst Ratings
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
Legend Biotech's CARVYKTI Advances and Strategic Positioning Amid Financial Resilience
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)
Express News | Legend Biotech Corp : Piper Sandler Cuts Target Price to $78 From $90
Genscript Reports on Legend Biotech's Q3 Financials
Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript Summary
Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript
Legend Biotech (LEGN) Gets a Hold From William Blair